Pfizer turns to app to overcome rare disease enrollment bottleneck

Pfizer ($PFE) is experimenting with a mobile app to enroll rare disease patients in a study. The trial is comparing the DNA of people with congenital analgesia to unaffected family members, but with just 40 new cases diagnosed each year, enrollment is a challenge. Pfizer hopes Sanguine Biosciences' mobile app can help by enabling remote data collection. Article

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.